David Killion, MD
Urology · Tucson, AZNPI 1619979952
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 246 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $876 and has fallen 57.2% since, to $375 in 2025. That places this record below the midpoint for urology clinicians in AZ, where the typical reported total is $3,799.
Across 246 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$727
- Coloplast$428
- Myovant Sciences Inc.$381
- 180 Medical, Inc.$375
- Astellas Pharma US Inc$346
- Bayer$322
- plus $2K from 31 others
Across 17 payments — averaging $45.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$765
What the payments were for
- Food & beverage$4,42498%
- Education$882%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 31 | $727 |
| Coloplast | 28 | $428 |
| Myovant Sciences Inc. | 22 | $381 |
| 180 Medical, Inc. | 21 | $375 |
| Astellas Pharma US Inc | 20 | $346 |
| Bayer | 18 | $322 |
| Amgen | 16 | $258 |
| Johnson & Johnson | 10 | $206 |
| Dendreon Pharmaceuticals LLC | 10 | $193 |
| Pfizer | 14 | $186 |
| AbbVie(2 entities) | 6 | $110 |
| Tolmar Pharmaceuticals, Inc. | 5 | $105 |
| Boston Scientific | 5 | $100 |
| Urogen Pharma, Inc. | 5 | $85 |
| Teleflex LLC | 3 | $81 |
| Tolmar, Inc. | 3 | $61 |
| Olympus America Inc. | 3 | $54 |
| Ferring Pharmaceuticals Inc. | 3 | $52 |
| Neotract Inc. | 3 | $51 |
| Progenics Pharmaceuticals, Inc. | 2 | $46 |
| Smith+Nephew | 2 | $33 |
| Caldera Medical, Inc | 1 | $33 |
| Novartis | 1 | $29 |
| Laborie Medical Technologies Corp. | 1 | $27 |
| Axonics, Inc. | 1 | $23 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $21 |
| Urovant Sciences Inc | 1 | $20 |
| Cardinal Health 414 LLC | 1 | $20 |
| Blue Earth Diagnostics | 1 | $19 |
| Merck | 1 | $19 |
| Sanofi | 1 | $17 |
| AstraZeneca | 1 | $16 |
| Verity Pharmaceuticals Inc. | 1 | $16 |
| Endo USA, Inc. | 1 | $14 |
| Mission Pharmacal Company | 1 | $13 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
| Rochester Medical Corporation | 1 | $12 |
How this compares
$4,512 in reported general payments places this provider in the 50th percentile of 269 urology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 38 | $540,194 |
| GemtesaVibegron | 142 | $110,355 |
| OrgovyxRelugolix | 36 | $94,709 |
| MyrbetriqMirabegron | 87 | $79,914 |
| Abiraterone Acetate | 48 | $36,407 |
| Tamsulosin Hcl | 809 | $14,483 |
| Oxybutynin Chloride ErOxybutynin Chloride | 285 | $6,228 |
| Finasteride | 354 | $5,410 |
| Potassium Citrate ErPotassium Citrate | 20 | $2,868 |
| Tolterodine Tartrate ErTolterodine Tartrate | 16 | $2,374 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 11 | $2,057 |
| Testosterone | 17 | $2,023 |
| NitrofurantoinNitrofurantoin Macrocrystal | 36 | $1,568 |
| Testosterone Cypionate | 95 | $1,474 |
| Terazosin Hcl | 54 | $1,450 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $346 | $620,107125 claims |
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $727 | $205,064178 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 269 urology providers in Arizona.
Other urology in Tucson
- Mitzi BarmatzTucson$135K
- Curtis DunsheeTucson$46K
- Susan KalotaTucson$30K
- Kalpesh PatelTucson$26K
- Tristan BerryTucson$14K
- Aleksandar BlubaumTucson$11K
- Mitchell HumphreysPhoenix$358K
- Shawn BlickGoodyear$336K
- Daniel JaffeePhoenix$280K
- Rahul MehanMesa$277K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.